SEOUL, South Korea, July 29, 2025 /PRNewswire/ -- Rebellions Inc., a leading AI semiconductor company based in South Korea, today announced a collaboration with Marvell Technology, Inc. (NASDAQ: MRVL) to offer high-performance, energy-efficient AI systems tailored for regionally driven and sovereign-backed AI initiatives across APAC and the Middle East.
As AI infrastructure becomes increasingly central to national competitiveness, a shift is underway from standardized, GPU-based architectures toward domain-specific systems built around custom ASICs. This change is being driven not only by global hyperscalers, but also by sovereign-backed initiatives and regional cloud providers seeking infrastructure that delivers scalability, efficiency, and control.
This collaboration will enable Rebellions to design customer-specific AI accelerators utilizing Marvell® custom platforms—leveraging advanced packaging, high-speed SerDes and die-to-die interconnects resulting in a tightly integrated, end-to-end rack solution built for high-performance, energy-efficient AI inference at scale.
"AI infrastructure is undergoing a fundamental shift—organizations are no longer settling for one-size-fits-all solutions," said Sunghyun Park, CEO of Rebellions. "By collaborating with Marvell, we're combining deep expertise in AI chip design with cutting-edge silicon integration to deliver custom AI infrastructure designed to meet the real-world needs of sovereign entities."
"Custom AI infrastructure is key to unlocking the next wave of data center innovation," said Will Chu, Senior Vice President and General Manager of Custom Cloud Solutions at Marvell. "We look forward to collaborating with Rebellions to offer next-generation custom AI infrastructure tailored for performance, efficiency and scalability."
About Rebellions
Rebellions develops AI accelerators optimized for Large Language Models and large-scale inference, delivering industry-leading energy efficiency. Its flagship chip REBEL uses chiplet architecture and 144GB HBM3E memory for massive-scale AI inference. The platform includes software for seamless data center integration. Building on its AI accelerator ATOM's proven mass-production experience since 2024, Rebellions is now backed by strategical investors including SK Telecom, SK hynix, Aramco's Wa'ed Ventures, and KT. Strengthened by its merger with SK SAPEON, Rebellions is Asia's leading independent AI semiconductor platform.
Marvell and the M logo are trademarks of Marvell or its affiliates. Please visit www.marvell.com for a complete list of Marvell trademarks. Other names and brands may be claimed as the property of others.
This press release contains forward-looking statements within the meaning of the U. S. federal securities laws that involve risks and uncertainties. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future events, results or achievements. Actual events, results or achievements may differ materially from those contemplated in this press release. Forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict, Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and no person assumes any obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Rebellions Announces Collaboration with Marvell to Deliver Custom AI Infrastructure for Sovereign-Scale Deployments
|
CARDIFF-BY-THE-SEA, Calif., Jan. 12, 2026 /PRNewswire/ -- Field Medical Inc., a clinical-stage medical technology company advancing a versatile, next-generation pulsed field ablation (PFA) platform designed to support both ventricular tachycardia (VT) and atrial fibrillation (AF) ablation, today announced that its founder, Steven Mickelsen, MD, will present at the 44th annual J.P. Morgan Healthcare Conference on Thursday, Jan. 15, 2026, at 10 a.m. PT at The Westin St. Francis in San Francisco.
The presentation will feature a company overview, including the FieldForce™ PFA platform, clinical progress in VT, the Field-PULSE AF study, and plans for the upcoming pivotal VT trial.
Field Medical's leadership team will be available for meetings during the conference. To request a meeting, please email ir@fieldmedicalinc.com.
About Field Medical® Inc.
Founded in 2022, Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce™ Ablation System integrates a focal catheter design with proprietary FieldBending™ energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X and YouTube.
The FieldForce™ Ablation System is an investigational device and is limited by federal (or U.S.) law to investigational use.
Contacts
Media
Holly Windler
619.929.1275
media@fieldmedicalinc.com
Investor Relations
ir@fieldmedicalinc.com
CARDIFF-BY-THE-SEA, Calif., Jan. 12, 2026 /PRNewswire/ -- Field Medical Inc., a clinical-stage medical technology company advancing a versatile, next-generation pulsed field ablation (PFA) platform designed to support both ventricular tachycardia (VT) and atrial fibrillation (AF) ablation, today announced that its founder, Steven Mickelsen, MD, will present at the 44th annual J.P. Morgan Healthcare Conference on Thursday, Jan. 15, 2026, at 10 a.m. PT at The Westin St. Francis in San Francisco.
The presentation will feature a company overview, including the FieldForce™ PFA platform, clinical progress in VT, the Field-PULSE AF study, and plans for the upcoming pivotal VT trial.
Field Medical's leadership team will be available for meetings during the conference. To request a meeting, please email ir@fieldmedicalinc.com.
About Field Medical® Inc.
Founded in 2022, Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce™ Ablation System integrates a focal catheter design with proprietary FieldBending™ energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X and YouTube.
The FieldForce™ Ablation System is an investigational device and is limited by federal (or U.S.) law to investigational use.
Contacts
Media
Holly Windler
619.929.1275
media@fieldmedicalinc.com
Investor Relations
ir@fieldmedicalinc.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Field Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
